Garmin Fenix 9 Has 94 Bugs a Month After Launch
Oura Sued Over Its 95% Sleep Accuracy Claim
Oura’s whole pitch rests on one number: 95%. That’s the sleep-staging accuracy the company advertises against a clinical sleep lab, and it’s the stat this site has cited in comparison after comparison to explain why Oura sits at the top of the smart ring category. On August 20, 2026, a class-action complaint filed in the U.S. District Court for the Northern District of California argued that number doesn’t hold up, and it’s landing at the worst possible moment for a company reportedly weeks from going public.
Case 3:26-cv-08686, Surber v. Oura Inc. et al., was brought by Clarkson Law Firm on behalf of Madison Surber, a California resident who says she paid roughly $513.68 for an Oura Ring 4 Gold in May 2025 based on the company’s accuracy marketing. It’s the first direct legal challenge to a stat this site — and most of the wearables press — has treated as settled fact for years.
Quick Verdict
| What’s Known | |
|---|---|
| Filed | August 20, 2026, U.S. District Court for the Northern District of California |
| Case number | 3:26-cv-08686, Surber v. Oura Inc. et al. |
| Plaintiff / firm | Madison Surber, represented by Clarkson Law Firm |
| Claim being challenged | ”95% Sleep Staging Accuracy compared to a clinical sleep lab” (Oura’s current Ring marketing) |
| Key evidence cited | A March 2025 Scientific Reports study finding ~53% sleep-stage accuracy across 45 nights |
| Oura’s position | Disputes the claims; says its algorithm is built on 1,200+ nights of polysomnography data and “validated and compared favorably” in independent studies |
| Timing | Filed as Oura reportedly targets a U.S. IPO as soon as September 2026, seeking up to $3B at a valuation above $16B |
Best for: Anyone currently choosing between Oura and WHOOP, Ultrahuman, or a budget ring who wants to know the accuracy claim is contested before buying. Skip if: You need a final legal outcome. This just got filed — nothing here has been decided by a court.
What Does the Oura Lawsuit Allege?
Strip the complaint down to what it’s actually arguing, because the headline number obscures a more specific claim underneath it.
- Oura markets its rings as “built for accuracy” and capable of “unparalleled accuracy” in tracking sleep stages — wake, light, deep, and REM.
- The company has advertised two different accuracy figures over time: an earlier 79% claim, and more recently “95% Sleep Staging Accuracy compared to a clinical sleep lab” for the Ring 5 generation.
- The suit argues Oura’s hardware physically can’t back that number up. Clinical polysomnography — the actual gold-standard sleep lab test — relies on EEG and EOG sensors reading brain activity and eye movement directly. A ring using optical heart rate, temperature, and motion is estimating sleep stages, not measuring the same signals a sleep lab measures.
- It cites a March 2025 study published in Scientific Reports, part of the Nature portfolio, that tested Oura and two other ring trackers against real polysomnography across 45 nights and found Oura’s four-stage accuracy at roughly 53%, not 95%.
- Seven legal counts follow from that gap, including fraud by misrepresentation, unjust enrichment, and violations of California’s Unfair Competition Law, False Advertising Law, and Consumers Legal Remedies Act.
That’s the actual shape of the case: not “Oura doesn’t work,” but “the specific number in Oura’s ads doesn’t match what independent testing found.”
95% vs. 53%: Where the Numbers Actually Come From
Here’s the part worth slowing down on, because both sides are citing real research — they’re just measuring different things.
Oura’s 95% figure and the study’s 53% figure aren’t even the same kind of accuracy number, and that gap is going to matter a lot in court. Oura’s own published methodology, built on a dataset of more than 1,200 nights of clinical polysomnography data collected across five sleep lab sites, reports 79% agreement with polysomnography on four-stage classification (wake, light, deep, REM) and 96% on the simpler two-stage question of sleep versus wake. Where “95%” actually comes from in the current marketing copy — which sleep-stage comparison, on which ring generation — is one of the things the lawsuit says Oura hasn’t adequately shown.
The Scientific Reports study the plaintiffs lean on tested Oura, SleepOn, and Circul rings against overnight polysomnography in 45 patients in an actual clinical setting — not the healthy, uninterrupted sleepers most consumer validation studies recruit. Oura came out on top of the three rings tested, at 53.18% four-stage accuracy, but that’s still a long way from 95%, and the study specifically warned that decent average agreement can hide serious individual-level error. Someone whose ring says “great REM night” might be having the opposite experience.
Oura’s response, given to TechCrunch after the suit was filed, doesn’t back away from the number: “We stand behind our science, research, and accuracy claims. Like other consumer sleep wearables, Oura Ring estimates sleep stages using multiple physiological signals, including heart rate, heart rate variability, movement, breathing patterns, and temperature.” The company has also said its technology has been “validated and compared favorably” against polysomnography in multiple independent third-party studies, and that it isn’t marketed as a medical device.
Both of those things can be true at once — Oura’s algorithm can be the best-performing consumer ring in independent testing, and still fall well short of the 95% figure printed on its own marketing pages. That’s the gap the lawsuit is built around.
Why the Timing Actually Matters
This lawsuit would be notable on its own. It’s a lot more notable given what else is happening at Oura right now.
Oura is reportedly preparing a U.S. IPO as soon as September 2026, seeking to raise up to $3 billion at a valuation north of $16 billion — a sharp jump from the roughly $10.9 billion the company was valued at in its September 2025 funding round. A previous FCC filing on the Ring 5 already had this site tracking Oura’s IPO timeline months before the number got this large, and the valuation has more than doubled the trajectory we were watching back then.
Accuracy is not a side feature for Oura. It’s the entire premise of a $349 ring plus a $5.99-a-month subscription. Every S-1 filing that comes out of this IPO process is going to have to disclose the lawsuit as a legal risk to the business, in language lawyers, not marketers, get to write. Whether the case gets dismissed, settled, or drags into 2027 discovery, it’s now a line item public-market investors will read before they decide whether Oura’s growth story is worth $16 billion.
None of that means the lawsuit wins. Consumer class actions over marketing language get dismissed regularly, and “our number and your number measure different things” is a real defense, not just spin. But the suit doesn’t need to win to do damage — it just needs to exist while bankers are pricing shares.
Is Oura Ring Accurate?
Independent, non-litigation research generally puts Oura’s sleep-stage tracking ahead of most consumer wearables but meaningfully below its own marketing claims: roughly 53% to 79% four-stage accuracy against clinical polysomnography, depending on the study and population, versus the 95% figure in current ads. For total sleep time and sleep/wake detection, accuracy runs much higher, in the 90%+ range. The gap between “good sleep tracker” and “95% clinical-lab accurate” is exactly what this lawsuit is arguing about.
That’s consistent with what we’ve found in hands-on testing across this site. Every comparison we’ve run — against WHOOP, against Ultrahuman, against the budget Pebble Index 01 — has ranked Oura’s sleep staging at or near the top of the category. None of that changes today. What changes is that the specific number Oura puts on a product page now has a lawsuit attached to it, and “best in category” and “95% clinically accurate” are different claims that deserve different levels of trust.
What This Means If You’re Choosing a Ring Right Now
If you’re comparing Oura against WHOOP, Ultrahuman, a Galaxy Watch, or a budget ring like Pebble: the relative ranking probably hasn’t moved. Oura still tests well against its direct competitors in independent research. What’s changed is that the absolute number Oura advertises — 95% — is now formally disputed, so treat it as marketing copy under legal challenge rather than a verified spec.
If you already own an Oura Ring: nothing about your device’s function changes today. The lawsuit is about advertising language, not a product recall or a software issue. Recent updates like the 2026 app redesign are unaffected.
If you’re weighing an Oura purchase against the IPO timeline: the accuracy dispute is now part of the calculus, not just the subscription-cost math this site has run before. A pending class action doesn’t typically move hardware prices in the short term, but it’s one more variable in a company about to face public-market scrutiny for the first time.
Our Take
The core tension here isn’t really about whether Oura’s ring is good. By most independent accounts, it’s the best sleep-staging hardware in its category — that’s been true across everything we’ve tested it against on this site. The tension is about whether “95% Sleep Staging Accuracy compared to a clinical sleep lab” is a defensible claim or a marketing rounding error dressed up as a spec.
Our read: Oura’s own published research supports strong performance, but 79% on the company’s own dataset and 53% on someone else’s is a real spread, and neither number is 95% without a lot of fine print about what exactly is being measured. Companies get to pick the most favorable framing of their own data. That’s normal. Whether “95%” crosses from favorable framing into false advertising is now a question for a federal judge, not a marketing team, and that’s a meaningfully different position for Oura to be in three weeks before it potentially rings a public-market opening bell.
The Bottom Line
A California resident who paid $513.68 for a ring is now the named plaintiff in a case that could shape how every wearable company markets accuracy claims going forward, filed at the exact moment Oura is trying to convince investors it’s worth $16 billion. The ring itself hasn’t changed. The number on the box is now contested in federal court. If you’re deciding between Oura and its competitors this week, that’s a fact worth knowing before you hand over $349 plus a subscription for a claim that’s currently being litigated.
Details reflect the complaint filed August 20, 2026 in the U.S. District Court for the Northern District of California, reporting from TechCrunch on both the lawsuit and Oura’s IPO plans, and the March 2025 Scientific Reports study cited in the complaint. This post will be updated if Oura’s legal or IPO status changes.
